OneMedNet Corp: financial analysis
Ratios worked out from 6 fiscal years of OneMedNet Corp's statements, compared with 88 companies in Diagnostics and Research.
OneMedNet Corp scorecard#
Passes 4 of the 19 checks that could be worked out: strongest in growth (3 of 4), weakest in valuation (0 of 5). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation0 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
- ✗Price to sales below its peers' median11.8×Price to sales 11.8× against Diagnostics and Research's median of 4.5×.
- ✗Free cash flow yield above 5%-27.7%Free cash flow is -27.7% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 4.92% (2026-11-20).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth3 of 4
- ✓Revenue grew in the newest year112.5%Revenue up 112.5% in fiscal 2025.
- ✓Revenue up more than 5% a year over three years5.8%5.8% a year over the three years to fiscal 2025.
- ✓Faster growth over three years than its peers' median5.8%5.8% a year against Diagnostics and Research's median of 3.6% (64 companies).
- ✗Earnings per share grew in the newest year-0.06 vs -0.36Diluted EPS -0.06 in fiscal 2025 against -0.36 the year before (report's currency).
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 4
- ✗Profitable in the newest year-$3 MNet income -$3 M in fiscal 2025.
- ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-711.0%-711.0% against Diagnostics and Research's median of -2.4% (66 companies).
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- ✗Operating margin wider than three years earlier-711.0%-711.0% in fiscal 2025 against -671.3% in 2022.
Financial health1 of 5
- ✗Short-term assets cover short-term liabilities0.4×Current ratio 0.44 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $0 M at the end of fiscal 2025.
- ✗Operating income covers interest five times-138.1×Operating income -138.1 times interest in fiscal 2025.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-80.51Z-score -80.51 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year58.7%Diluted shares up 58.7% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Diagnostics and Research, the 10-year Treasury yield of Nov 20, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
What the 2025 statements show#
Each line is an observation with its numbers, not a judgement of the company.
Strengths
- More cash than debt: net cash of $0 million.
Worth a look
- Net loss of $3 million, the 4th loss-making year in a row.
- Free cash flow was negative: -$8 million.
- The share count rose 58.7% in the year.
- Shareholders' equity is negative: -$3 million.
- Operating income covers the interest bill only -138.1 times.
- Liabilities due within a year exceed current assets (current ratio 0.44).
- Receivables grew 138% while revenue grew 112%: customers are paying later, or sales were booked ahead of cash.
Piotroski F-score
Nine yes/no tests of whether the company's finances improved in the year. One point each.
- Made a profitno
- Operations brought in cashno
- Return on assets roseyes
- Cash from operations exceeds profitno
- Long-term debt fell against assetsyes
- Current ratio roseyes
- No new shares issuedyes
- Gross margin roseyes
- Asset turnover roseyes
Altman Z-score
A 1968 formula that weighs five balance-sheet ratios. It was built on listed manufacturers and says less about other kinds of company.
| Part | Ratio | Weight | Points |
|---|---|---|---|
| Working capital to assets | -1.26 | × 1.2 | -1.52 |
| Retained earnings to assets | -48.54 | × 1.4 | -67.96 |
| Operating income to assets | -4.50 | × 3.3 | -14.84 |
| Market value to liabilities | 5.29 | × 0.6 | 3.18 |
| Revenue to assets | 0.63 | × 1 | 0.63 |
Profitability#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Gross margin | -36.8% | — | -12.8% | -31.3% | — | 55.7% | 0% | |
| Operating margin | -711.0% | — | -671.6% | -671.3% | — | -2.4% | 2% | |
| Net margin | -205.9% | — | — | — | — | -3.6% | 9% | |
| Return on assets | -95.2% | -483.5% | — | -51.1% | 4.4% | -7.2% | 14% |
Growth#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Revenue growth | 112.5% | — | -11.3% | — | — | 6.6% | 96% | |
| Revenue growth, 3 years a year | 5.8% | — | — | — | — | 3.6% | 59% |
Financial strength#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Net debt | $-0 M | $2 M | $0 M | — | — | $270 M | 74% | |
| Interest cover | -138.14× | -64.00× | -685.00× | -19.30× | — | -3.31× | 11% | |
| Current ratio | 0.44× | 0.19× | 0.03× | 0.01× | 1.86× | 1.96× | 8% | |
| Equity share of assets | -137.7% | -427.6% | — | — | -6.0% | 51.6% | 3% |
Cash#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Free cash flow | $-8 M | $-7 M | $-5 M | $-5 M | — | $-2 M | 35% | |
| Free cash flow margin | -552.2% | — | -473.5% | -413.9% | — | 4.7% | 3% | |
| Cash conversion | — | — | — | — | -7.4% | 169.7% | — | |
| Capital spending share of revenue | 0.7% | — | 3.9% | 5.2% | — | 3.3% | — |
Efficiency#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Asset turnover | 0.46× | — | 1.17× | 0.02× | — | 0.63× | 34% |
How each figure is worked out#
- Gross margin
- Gross profit as a share of revenue.
- Operating margin
- Operating income as a share of revenue.
- Net margin
- Net income as a share of revenue.
- Return on assets
- Net income as a share of total assets (average of the year).
- Revenue growth
- Revenue against the year before.
- Revenue growth, 3 years a year
- The yearly rate that takes revenue of three years earlier to this year's.
- Net debt
- Total debt less cash. Negative means more cash than debt.
- Interest cover
- Operating income divided by the interest paid on debt.
- Current ratio
- Assets due within a year divided by liabilities due within a year.
- Equity share of assets
- Shareholders' equity as a share of total assets.
- Free cash flow
- Cash from operations less capital spending.
- Free cash flow margin
- Free cash flow as a share of revenue.
- Cash conversion
- Cash from operations as a share of net income. Only when the year was profitable.
- Capital spending share of revenue
- Capital spending as a share of revenue.
- Change in share count
- Diluted shares against the year before. Negative: fewer shares.
- Asset turnover
- Revenue divided by total assets (average of the year).